165 related articles for article (PubMed ID: 21699746)
21. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
Thakkar V; Nikpour M; Stevens WM; Proudman SM
Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
[TBL] [Abstract][Full Text] [Related]
22. [The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension].
Wang H; Tian Z; Liu Y; Li M; Wang Q; Zeng X; Fang Q
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):390-3. PubMed ID: 25146407
[TBL] [Abstract][Full Text] [Related]
23. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension.
Mathai SC; Sibley CT; Forfia PR; Mudd JO; Fisher MR; Tedford RJ; Lechtzin N; Boyce D; Hummers LK; Housten T; Zaiman AL; Girgis RE; Hassoun PM
J Rheumatol; 2011 Nov; 38(11):2410-8. PubMed ID: 21965638
[TBL] [Abstract][Full Text] [Related]
24. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
J Rheumatol; 2011 Nov; 38(11):2419-27. PubMed ID: 21965635
[TBL] [Abstract][Full Text] [Related]
26. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.
Lindholm A; Hesselstrand R; Rådegran G; Arheden H; Ostenfeld E
Clin Physiol Funct Imaging; 2019 May; 39(3):215-225. PubMed ID: 30597705
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
Hinchcliff M; Fischer A; Schiopu E; Steen VD;
J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
[TBL] [Abstract][Full Text] [Related]
28. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.
Calderone A; Stevens W; Prior D; Nandurkar H; Gabbay E; Proudman SM; Williams T; Celermajer D; Sahhar J; Wong PK; Thakkar V; Dwyer N; Wrobel J; Chin W; Liew D; Staples M; Buchbinder R; Nikpour M
BMJ Open; 2016 Dec; 6(12):e011028. PubMed ID: 27932335
[TBL] [Abstract][Full Text] [Related]
29. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Avouac J; Wipff J; Kahan A; Allanore Y
Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
31. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
[TBL] [Abstract][Full Text] [Related]
32. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE;
Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721
[TBL] [Abstract][Full Text] [Related]
33. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
[TBL] [Abstract][Full Text] [Related]
34. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China.
Huang J; Li M; Tian Z; Hsieh E; Wang Q; Liu Y; Xu D; Hou Y; Zhao J; Guo X; Lai J; Hu C; Song N; Sun Q; Sun Q; Zhang F; Zhao Y; Zeng X
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-115-21. PubMed ID: 25372797
[TBL] [Abstract][Full Text] [Related]
35. Update in systemic sclerosis-associated pulmonary arterial hypertension.
Gashouta MA; Humbert M; Hassoun PM
Presse Med; 2014 Oct; 43(10 Pt 2):e293-304. PubMed ID: 25179278
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary arterial hypertension in Thai patients with systemic sclerosis.
Wangkaew S; Kasitanon N; Phrommintikul A; Sukitawut W; Wichainun R; Louthrenoo W
J Med Assoc Thai; 2008 Feb; 91(2):166-72. PubMed ID: 18389980
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
[TBL] [Abstract][Full Text] [Related]
39. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with the 6-minute walk distance in patients with systemic sclerosis.
Sanges S; Giovannelli J; Sobanski V; Morell-Dubois S; Maillard H; Lambert M; Podevin C; Lamblin N; De Groote P; Bervar JF; Perez T; Matran R; Rémy-Jardin M; Hatron PY; Hachulla É; Launay D
Arthritis Res Ther; 2017 Dec; 19(1):279. PubMed ID: 29246248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
